Stryker (SYK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Lee Hambright from Bernstein maintained a Buy rating on the stock and has a $450.00 price target.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lee Hambright has given his Buy rating due to a combination of factors that highlight Stryker’s strong performance and future growth potential. The company’s first-quarter results showed impressive revenue growth of 10.1% organically, surpassing consensus expectations by 3%. This growth was consistent across various regions and segments, indicating a robust business model.
Furthermore, Stryker has effectively managed a $200 million tariff impact and adjusted its guidance to reflect the Inari acquisition. The company is poised for continued above-market growth driven by factors such as the adoption of robotic-assisted surgery, favorable demographics, and strong procedure volumes. Additionally, the integration of Inari is on track, and upcoming product launches are expected to drive further growth. These elements, combined with a raised price target of $450, underpin the Buy rating.
According to TipRanks, Hambright is a 4-star analyst with an average return of 9.3% and a 68.75% success rate. Hambright covers the Healthcare sector, focusing on stocks such as Dexcom, Abbott Laboratories, and Boston Scientific.
In another report released today, Barclays also maintained a Buy rating on the stock with a $443.00 price target.